Human Leukemia Antigen (HL-60) / PADI4 (Monocyte Marker) Antibody [IPO-M6]

Summary

This antibody reacts with human leukemia cell line HL-60 and immunoprecipitates two proteins with MW of 48 kDa and 52 kDa. It does not stain B-cell lines Daudi, PHS, Namalwa, RPMI-1788 and T-cell lines CCRF-HSB2, Jurkat and Molt-4. This antibody stains monocytes and up to 10% of lymphocytes from peripheral blood of healthy donors. Blast cells of patients with AMMonL (M5 following FAB classification), AMMonL (M4) and hairy cells leukemia are positive. Its antigen is particularly expressed on blood cells from patients with infectious mononucleosis and CLL. Histiocytes and macrophages are also positive. Malignant cells from patients with AML (M1 and M2), T-ALL, B-ALL are not stained. HL-60 cells are used as an in vitro model of acute promyelocytic leukemia and for differentiation and apoptosis studies. The HL60 cell line was established in 1977 from a patient with acute myeloid leukemia. The cells largely resemble promyelocytes but can be induced to differentiate terminally in vitro. Some reagents cause HL60 cells to differentiate to granulocyte-like cells, others to monocyte/macrophage-like cells. The HL60 cell genome contains an amplified c-myc proto-oncogene; c-myc mRNA levels are correspondingly high in undifferentiated cells but decline rapidly following induction of differentiation.